Pliant Therapeutics Inc
$ 1.15
-1.71%
05 Jun - close price
- Market Cap 71,208,000 USD
- Current Price $ 1.15
- High / Low $ 1.18 / 1.13
- Stock P/E N/A
- Book Value 2.67
- EPS -1.83
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.54 %
- 52 Week High 1.95
- 52 Week Low 1.09
About
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$2.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-11 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-03 | 2024-11-07 | 2024-08-07 | 2024-05-06 | 2024-02-27 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -0.32 | -0.3539 | -0.43 | -0.71 | -0.92 | -0.82 | -0.95 | -0.92 | -0.78 | -0.69 | -0.7 | -0.7 |
| Estimated EPS | -0.358 | -0.4162 | -0.56 | -0.6595 | -0.7469 | -0.9552 | -0.97 | -0.85 | -0.77 | -0.81 | -0.77 | -0.71 |
| Surprise | 0.038 | 0.0623 | 0.13 | -0.0505 | -0.1731 | 0.1352 | 0.02 | -0.07 | -0.01 | 0.12 | 0.07 | 0.01 |
| Surprise Percentage | 10.6145% | 14.9688% | 23.2143% | -7.6573% | -23.1758% | 14.1541% | 2.0619% | -8.2353% | -1.2987% | 14.8148% | 9.0909% | 1.4085% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLRX
2026-05-21 17:29:00
Pliant Therapeutics announced an upcoming presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation will detail the FORTIFY study, a Phase 1b indication expansion trial of PLN-101095, an integrin inhibitor, in combination with pembrolizumab for patients with ICI-refractory advanced solid tumors. The company is currently enrolling patients in this trial, focusing on non-small cell lung cancer, high tumor mutational burden tumors, or clear cell renal cell carcinoma.
2026-05-12 16:09:22
This article provides details on Pliant Therapeutics, Inc. (MUN:9PT), listed on the Munich Stock Exchange, focusing on its financial data related to the number of shareholders. It appears to be a stub or data placeholder showing periods and values for shareholder changes. The content emphasizes financial information from sources like ICE Data Services and FactSet.
2026-05-12 06:40:22
Pliant Therapeutics (NASDAQ: PLRX) significantly reduced its net loss to $20.0 million in Q1 2026 from $56.2 million in Q1 2025, primarily due to restructuring efforts and a pivot to oncology. The company maintains a strong cash position of $172.4 million, which is expected to fund operations for at least the next 12 months. Pliant is advancing its lead oncology program, PLN-101095, with a Phase 1b trial underway and updated Phase 1 data showing anti-tumor activity.
2026-05-11 19:40:22
Pliant Therapeutics reported a significantly narrowed net loss of $20.0 million in Q1 2026, down from $56.2 million year-over-year, largely due to reduced operating expenses after portfolio restructuring. The company advanced its lead oncology program, PLN-101095, into a Phase 1b trial and presented encouraging early Phase 1 data showing promising responses in checkpoint inhibitor-refractory solid tumors. Pliant also maintains a strong cash position of $172.4 million, sufficient to fund operations into the second half of 2028.
2026-05-11 19:40:22
Pliant Therapeutics has provided a corporate update and reported its first-quarter 2026 financial results. The company highlighted the initiation of its FORTIFY Phase 1b trial for PLN-101095 and positive updated data from the Phase 1 trial, showing deepening responses in patients with solid tumors. Pliant also discussed its integrin-targeted delivery platform and reported a net loss of $20.0 million for the quarter, with sufficient cash to fund operations into the second half of 2028.
2026-05-11 19:40:22
Pliant Therapeutics reported a Q1 2026 net loss of $20.0 million, significantly reduced from $56.2 million in the prior year, primarily due to lower operating expenses and decreased headcount. The company also announced positive updated data from its Phase 1 trial of PLN-101095, an oral cancer therapy, showing confirmed responses in patients with ICI-refractory solid tumors, and initiated its FORTIFY Phase 1b indication expansion trial. Pliant expects its current cash and investments of $172.4 million to fund operations into the second half of 2028.
